# US 2022/0017611 A1 · New anti tau svqivykpv epitope single domain antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017611 A1
- Document ID: US20220017611A1
- Status: Published application
- Kind: A1
- Application number: 17/413,215
- Filed: 2019-12-12
- Published: 2022-01-20
- Earliest claimed: 2018-12-13
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite De Lille; Centre Hospitalier Regional Universitaire De Lille; Centre National de la Recherche Scientifique (CNRS); Hybrigenics Services S.A.S.
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Université De Lille; Centre Hospitalier Regional Universitaire De Lille; Centre National De La Recherche Scientifique (Cnrs); Hybrigenics Services SAS
- Inventors: Luc BUEE; Isabelle LANDRIEU; Jean-Christophe RAIN; Elian DUPRE; Alexis ARRIAL; Clément DANIS
- Web page: https://patentgrep.com/patent/US20220017611A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2800/2821: Alzheimer
- G01N 2800/2828: Prion diseases
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to generation, optimization and characterisation of VHH targeted against Tau MTBD (microtubule-binding domain) with high affinity, obtained by screening from a naïve synthetic library. The inventors optimized version of a lead VHH which is able to inhibit Tau aggregation in vitro and in HEK 293 aggregation-reporting cellular model, providing a new tool in Tau immunotherapies. Accordingly the invention relates to new VHH antibody that specifically binds with high affinity Tau species, especially the epitope region involved in Tau aggregation. Moreover, the inventors found that immunization with the optimized version of this lead VHH prevented the formation of neurofibrillary tangles induced by injection of extracellular h-AD in mouse model. Thus, these specific antibodies can be used for the therapy of tauopathy disorders such as Progressive supranuclear palsy (PSP).

## Claims

### Claim 1

An isolated anti-Tau single domain antibody, wherein said isolated anti-Tau single domain antibody binds to an epitope comprising residues SVQIVYKPV (SEQ ID NO:1) of the Tau protein with a KD of 150 nM or less, 80 nM or less, or 50 nM or less.

### Claim 2 (depends on 1)

The isolated anti-Tau single domain antibody according to claim 1 wherein the isolated anti-Tau single domain antibody comprises a variable heavy chain having at least 70% of identity with sequence set forth as SEQ ID NO:2.

### Claim 3 (depends on 2)

The isolated anti-Tau single domain antibody according to claim 2, wherein said isolated anti-Tau single domain antibody comprises a variable heavy chain (VH) having an amino acid sequence as set forth as SEQ ID NO:2

### Claim 4 (depends on 1)

The isolated anti-Tau single domain antibody according to claim 1 which is a humanized single domain antibody.

### Claim 5 (depends on 1)

The isolated anti-Tau single domain antibody according to claim 1 wherein said isolated anti-Tau single domain antibody has a heavy chain comprising i) a VH-CDR1 having at least 7, 6, 5, 4, 3, 2, or 1 conservative substitutions within the VH-CDR1 of single domain antibody Z70 (SEQ ID No 3), ii) a VH-CDR2 having at least having at least 7, 6, 5, 4, 3, 2, or 1 conservative substitutions within the VH-CDR2 of single domain antibody Z70 (SEQ ID No 4) and iii) a VH-CDR3 having at least 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 conservative substitutions within the VH-CDR3 of single domain antibody Z70 (SEQ ID No 5).

### Claim 6 (depends on 5)

The isolated anti-Tau single domain antibody according to claim 5, wherein said isolated anti-Tau single domain antibody comprises a CDR1 having a sequence set forth as SEQ ID NO: 3, a CDR2 having a sequence set forth as SEQ ID NO:4 and a CDR3 having a sequence set forth as SEQ ID NO:5.

### Claim 7 (depends on 1)

The isolated anti-Tau single domain antibody according to claim 1, which comprises a heavy chain framework region sharing a homology or identity of 80% or more with a framework region having an amino acid sequence consisting of SEQ ID NOs: 8 to 11.

### Claim 8 (depends on 1)

The isolated anti-Tau single domain antibody according to claim 1 wherein said isolated anti-Tau single domain antibody is able to reduce the level of pathological aggregation of Tau protein.

### Claim 9

An isolated anti-Tau single domain antibody, comprising a heavy chain having the following sequences:
VH FR1:
(SEQ ID NO: 21)
M-A-E-V-Q-L-Q-A-S-G-G-V-F-V-Q-
S-G-G-S-L-R-L-Xaa1-C-A-A-S-G
wherein Xaa1 is Serine (S) or Cysteine (C);
VH-CDR1:
(SEQ ID NO: 22)
A-T-S-Xaa2-F-D-G
wherein Xaa2 is Threonine (T) or Cysteine (C);
VH-FR2:
(SEQ ID NO: 23)
M-G-W-F-R-Q-A-P-G-K-E-Xaa3-E-F-V-S-A-I-S
wherein Xaa3 is Arginine (R) or Lysine (K);
VH-CDR2:
(SEQ ID NO: 24)
Y-Xaa4-Q-G-S-Y-T
wherein Xaa4 is Glutamic acid (E) or Glycine (G);
VH-FR3:
(SEQ ID NO: 25)
Y-Y-A-D-S-V-K-G-R-F-T-I-S-R-D-N-S-K-N-M-V-Y-L-
Q-M-N-S-L-Xaa5-A-E-D-T-A-Xaa6-Y-Y-C-A
wherein Xaa5 is Arginine (R) or Glycine (G)
and Xaa6 is Threonine (T)) or Serine (S);
VH-CDR3:
(SEQ ID NO: 26)
Xaa7-A-Y-E-G-D-L-Y-A-F-D-S
wherein Xaa7 is Proline (P) or Serine (S); and
VH-FR4:
(SEQ ID NO: 27)
Y-Xaa8-Xaa9-Q-G-T-Q-V-T-V-S-S-
wherein Xaa8 is Glycine (G) or Glutamic acid (E)
and Xaa9 is Glycine (G) or Glutamic acid (E).

### Claim 10 (depends on 9)

The isolated anti-Tau single domain antibody according to claim 9, wherein Xaa5 is Arginine (R); Xaa7 is Proline (P) and Xaa8 is Glycine (G).

### Claim 11 (depends on 1)

A nucleic acid sequence encoding the isolated anti-Tau single domain antibody according to claim 1.

### Claim 12 (depends on 11)

A vector comprising a nucleic acid sequence according to claim 11.

### Claim 13 (depends on 1)

An in vitro method for detecting human Tau peptide in a biological sample, comprising
contacting the biological sample with the anti-Tau single domain antibody according to claim 1 under conditions under conditions that permit formation of an immune complex between the human Tau peptide and the anti-Tau single domain antibody, and
detecting and/or measuring the immune complex that is formed.

### Claim 14

(canceled)

### Claim 15 (depends on 1, 12)

A pharmaceutical composition comprising the isolated anti-Tau single domain antibody according to claim 1, or a vector according to claim 12.

### Claim 16 (depends on 15)

A method of treating a tauopathy in a subject in need thereof, comprising,
administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 15.

### Claim 17 (depends on 16)

The method of claim 16, wherein the tauopathy is selected from the group consisting of Alzheimer's Disease Down syndrome; Guam parkinsonism dementia complex; Dementia pugilistica; myotonic dystrophies; Niemann-Pick disease type C; Pick disease; argyrophilic grain disease; Fronto-temporal dementia; Cortico-basal degeneration; Pallido-ponto-nigral degeneration; Progressive supranuclear palsy; and a Prion disorder.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the tauopathy is Progressive supranuclear palsy (PSP).

### Claim 19

(canceled)

### Claim 20 (depends on 17)

The method of claim 17, wherein the Prion disorder is Gerstmann-Sträussler-Scheinker disease with tangles.
